MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression implicated in cancer, which play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. The aim of this study was to investigate whether miR-30c mediated the resistance of breast cancer cells to the chemotherapeutic agent doxorubicin (ADR) by targeting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ). miR-30c was downregulated in the doxorubicin-resistant human breast cancer cell lines MCF-7/ADR and MDA-MB-231/ADR compared with their parental MCF-7 and MDA-MB-231 cell lines, respectively. Furthermore, we observed that transfection of an miR-30c mimic significantly suppressed the ability of MCF-7/ADR to resist doxorubicin. Moreover, the anti-apoptotic gene YWHAZ was confirmed as a target of miR-30c by luciferase reporter assay, and further studies indicated that the mechanism for miR-30c on the sensitivity of breast cancer cells involved YWHAZ and its downstream p38 mitogen-activated protein kinase (p38MAPK) pathway. Together, our findings provided evidence that miR-30c was one of the important miRNAs in doxorubicin resistance by regulating YWHAZ in the breast cancer cell line MCF-7/ADR.
Introduction
Breast cancer is the most commonly diagnosed cancer worldwide among women and is expected to account for 29% of all new cancer cases (1) . Surgery combined with chemotherapy is the current treatment of choice. However, chemotherapeutic failure frequently contributes to morbidity in patients diagnosed with breast cancer (2) , and the acquisition of resistance to doxorubicin is a major clinical obstacle to successful treatment. Consequently, it is essential to elucidate the signaling and regulatory mechanisms that are involved in doxorubicin resistance, which will be helpful for designing new and targeted therapeutic strategies that can overcome drug resistance for the treatment of breast cancer.
MicroRNAs (miRNAs) are a class of small noncoding RNAs, which could bind mRNAs of potentially harmful genes at the 39-untranslated region (39-UTR) with perfect or near-perfect complementarity, resulting in degradation or inhibition, respectively, of the target mRNA (3) . Generally, one miRNA can modulate hundreds of target genes and one gene can be repressed by hundreds of miRNAs, which results in the formation of complex regulatory pathways. Recently, experimental evidence revealed that miRNAs have been shown to function as regulatory molecules by inhibiting protein translation and to play an important role in development, differentiation, cell proliferation, and apoptosis (3). More recently, some studies suggested that miRNAs are involved in tumor cell resistance and/or sensitivity to chemotherapeutic agents (4) . For example, Zhu et al. (5) reported that both miR-451 and miR-27 are involved in the resistance of MCF-7 breast cancer cells to the chemotherapeutic drug doxorubicin mediated by MDR-1 (5, 6) .
Recent studies suggested that miRNA-30c (miR-30c) is one of the most commonly known tumor suppressor miRNAs, which belongs to the miR-30 family and plays an important role in cell death, invasion, and differentiation (7) (8) (9) . Bockhorn et al. (10) conducted an miRNA profiling study of clinical breast tumors to show that miR-30c had higher expression levels in luminal A tumors and lower levels in claudin-low and basal-like breast tumors, and overexpression of miR-30c could inhibit human breast cancer chemotherapy resistance by regulating twinfilin1 (TWF1) and interleukin-11. Similarly, in this study, we found that the level of miR-30c is lower in doxorubicin (ADR)-resistant human breast cancer cell lines MCF-7/ ADR and MDA-MB-231/ADR compared with their parental cell lines MCF-7 and MDA-MB-231, respectively. Interestingly, our study provided another novel mechanism for understanding doxorubicin resistance, that is, miR-30c could sensitize breast cancer cells to doxorubicin by targeting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta polypeptide (YWHAZ), a crucial factor in drug resistance.
Material and Methods

Cell lines and cell culture
Human breast cancer cell lines MCF-7 and MDA-MB-231 were maintained in our laboratory. The breast doxorubicin-resistant cancer cell line MCF-7/ADR was obtained from the Shanghai Institute of Cell Biology (China). Another breast doxorubicin-resistant cancer cell line MDA-MB-231/ADR was established by our laboratory. The method of detecting inducible resistance to doxorubicin was as follows. We continuously added doxorubicin to the growth medium of MDA-MB-231 cells, with a final concentration of 0.1 mg/mL. After several passages, clones generated in the presence of doxorubicin were selected as doxorubicin-resistant cancer cells, which had been cultured for more than 6 months in the medium supplemented with doxorubicin to assure that they were truly resistant to doxorubicin. MCF-7 and MDA-MB-231 cell lines were cultured in high-glucose DMEM (Gibco, USA) supplemented with 10% fetal calf serum (Gibco), and 1% penicillin and streptomycin (Invitrogen, USA) at 376C in a humidified atmosphere with 5% CO 2 . Doxorubicin-resistant cancer cell lines were cultured with 5% CO 2 at 376C in DMEM supplemented with 10% fetal calf serum, 1% penicillin and streptomycin, and 1 mM insulin. To maintain the ADRresistant phenotype, doxorubicin was added to the culture media at a final concentration of 1 mg/mL MCF-7/ADR and 0.1 mg/mL MDA-MB-231/ADR cells, and they were cultured for 2 weeks in ADR-free medium prior to their use in the experiment.
miRNA transfection
The miR-30c mimic and its negative control miRNAs were purchased from Shanghai GenePharma Company (China). miR-30c mimic sequences were 39-CGACUCUCACAUCCUACAAAUGU-59. We plated cells onto a 6-well plate at a density of 1610 5 cells per well 24 h before transfection with 80 nM miR-30c mimic and its negative control by using Lipofectamine 2000 reagent according to the manufacturer's protocol (Invitrogen). We generally harvested the transfected cells for studies after culturing for 48 h. Three independent experiments were performed.
RNA extraction and quantitative real-time PCR (qRT-PCR) analysis of miRNA Small RNAs were extracted from cultured cells by using the RISO TM RNA ISOlation Reagent (Biomics, USA) following the manufacturer's protocol. qRT-PCR for mature miR-30c was done with the TaqMan stem-loop kit and the TaqMan Universal PCR Master Mix from Applied Biosystems (USA) using the Applied Biosystems AB 7500 real-time PCR system, as described by Chen et al. (11) , with U6 small nuclear RNA used as endogenous control for data normalization. The primers for miR-30c were forward: 59-TGTGTAAACATCCTACACTCTCAG-39 and reverse: 59-GAGTAAACAACCCTCTCCCA-39. All reactions were run in triplicate, and miRNA expression was calculated using the 2 -DDCT method.
qRT-PCR analysis of mRNA expression Total RNA was isolated with TRIzol 1 reagent (Invitrogen) according to the manufacturer's protocol. cDNA was synthesized with the RevertAid First-Strand cDNA Synthesis Kit (Fermentas, USA) according to the manufacturer's instructions. After the reverse transcription reaction, qRT-PCR was conducted in an ABI 7500HT fast real-time PCR System (Applied Biosystems). The relative amount of each mRNA was normalized to b-actin. Primer sequences used for real-time PCR were as follows: YWHAZ forward and reverse primers were 59-ATGTACTT GGAAAAAGGCCG-39 and 59-CCCTGCTCTTGAGGAGC TTA-39, respectively, and b-actin forward and reverse primers were 59-GCACCACACCTTCTACAATG-39 and 59-TGCTTGCTGATCCACATCTG-39, respectively. All real-time PCR assays were conducted in triplicate. The expression levels of each analyte compared with untreated controls was assessed using the 2 -DDCT method.
Western blot analysis
Total cellular extracts were prepared by homogenization of 3610 6 to 5610 6 cells in radioimmunoprecipitation assay buffer (Sigma, USA). Equal amounts of proteins (50 mg) were separated by SDS-polyacrylamide gel electrophoresis on slab gels of 8 or 12% polyacrylamide and transferred to nitrocellulose membranes (Millipore Corp., USA). Membranes were incubated with mouse monoclonal antibodies against YWHAZ (1:400, Santa Cruz Biotechnology, USA) and rabbit monoclonal antibodies of phosphorylated (p)-p38 mitogen-activated protein kinase (MAPK) (1:500, Santa Cruz Biotechnology), and b-actin (1:1000, Cell Signaling, USA) was used as an internal control for protein loading. Antibody binding was revealed by incubation with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology). Signal detection used an enhanced chemiluminescence kit miR-30c and ADR resistance in breast cancer cells(Thermo Scientific, USA) and the ImageJ software system (NIH, USA).
Luciferase reporter assay
For the luciferase reporter experiments, the 39-UTR sequence of YWHAZ was amplified by PCR from human genomic DNA using primers that included XbaI and EcoRI tails on the 59 and 39 strands, respectively. Primers for YWHAZ 39-UTR were forward: 59-CCGCTCGAGCCGGC CTTCCAACCTTTGTC-39 and reverse: 59-GAATGCGGC CGCTCCCATCATCAATATTTATTGAGCATTTAC-39. PCR products were restricted with both XbaI and EcoRI restriction endonucleases, and then gel-purified mutations within the putative miR-30c binding sites were performed using a QuikChange site-directed mutagenesis kit (Stratagene, USA). Cells were transfected with the firefly luciferase UTR-report vector, 20 ng control Renilla luciferase pRL-TK vector (Promega, USA), and 10 nM miR30c mimic or a mimic control for the YWHAZ-39-UTR construct using Lipofectamine 2000 reagent. Forty-eight hours after transfection, cells were lysed with a 16 passive lysis buffer, and assays were performed using the Dual-Luciferase 1 Reporter Assay System kit (Promega) according to the manufacturer's instructions.
Drug sensitivity assay
Nontransfected or transfected breast cancer cells were seeded onto 96-well plates with 0.5610 4 per well in growth medium and incubated at 376C in a humidified 5% CO 2 atmosphere for 48 h, and then treated with doxorubicin (Qilu Pharmaceutical Factory, China) at a concentration range of 0.025 to 0.8 mg/mL for MCF-7 and 0.5 to 16 mg/mL for MCF-7/ADR, respectively. Forty-eight hours after doxorubicin treatment, 10 mL CCK-8 solution was added to the medium, and the cells were incubated at 376C for 3 h. The absorbance was read at 570 nm with a microplate spectrophotometer. Doxorubicin concentrations leading to 50% cell death (IC 50 ) were determined by a CCK-8-dependent cell viability assay. Three independent experiments were performed.
Apoptosis assay
Doxorubicin was added to the cell medium at a final concentration of 1 mM 48 h after transfection. After 24-h incubation, cells were collected and assayed with an Annexin V Apoptosis Detection Kit (Beyotime, China) on a BD FACSCalibur TM System (Becton Dickson, USA) following the manufacturer's instructions. Early apoptotic cells were defined as Annexin-V-positive, propidium iodidenegative cells. Each experiment was performed three times.
Doxorubicin accumulation
Cells transfected with miR-30c mimic or negative control were treated with 5 mM doxorubicin. After 2-h incubation, cells were washed three times with PBS and observed under a fluorescence microscope with a 4006 lens. Quantifications of doxorubicin fluorescence intensity were performed using the ImageJ software.
Small interfering RNA (siRNA) transfection siRNA specific for YWHAZ was chemically synthesized (Guangzhou RuiBio Corp., China) with the following sequence: AGUUCUUGAUCCCCAAUGC-dTdT. Lipofectamine 2000 transfection reagent was mixed with siRNA in a 1:1 ratio (v/v) for 20 min. Cells were incubated with serum-free DMEM (60 nM) as negative control or YWHAZ siRNA for 6 h, and then replaced with regular medium. Forty-eight hours after transfection, the cells were prepared for further analysis. siRNA transfection efficiency was measured with flow cytometry by calculating the percentage of fluorescein-labeled cells. The transfection efficiency was approximately 80%.
MCF-7/ADR-bearing nude mouse model and in vivo treatment
For preparation of the subcutaneous model, MCF-7/ ADR cells were propagated in 6-week-old nude mice by weekly transfer of 50 mL PBS containing 5610 5 cells. Mice received a subcutaneous (sc) injection of the cells under the shoulder. After sc implantation of the cells, when the sc tumor was approximately 100 mm 3 in size, mice were randomly allocated to groups consisting of five animals each, and 10 nmol miR-30c or mimic negative control in 0.1 mL saline buffer was locally injected into the tumor mass every 3 days for 2 weeks. Drug administration was given via intraperitoneal injection of 50 mL PBS containing 1 mg/kg doxorubicin, one dose every other day, with three doses total. We monitored tumor growth starting on the first day of treatment and measured the volume of the xenograft every 4 days. Tumor volume (V) was estimated according to the formula: V=A6B 
Statistical analysis
All statistical analyses were performed using the SPSS12.0 software (USA). The difference between means was analyzed with the Student t-test. P values of ,0.05 were considered to be statistically significant. All data are reported as means±SD.
Results
Downregulation of miR-30c correlated with overexpression of YWHAZ in breast doxorubicin-resistant cells
To explore the role of miR-30c in doxorubicin resistance, we first compared miR-30c expression between the breast doxorubicin-resistant cancer cells and their parental doxorubicin-sensitive cells. Using miRNA real-time qRT-PCR analysis, we observed a differential expression pattern between them. As shown in Figure 1A , miR-30c expression in MCF-7/ADR was 6.7-fold lower than in MCF-7, and expression was also decreased (1.9-fold) in MDA-MB-231/ADR, compared to its parental cell line MDA-MB-231. We subsequently performed a Western blot to detect the expression of YWHAZ. As expected, the expression level of YWHAZ was higher in the doxorubicin-resistant MCF-7/ADR and MDA-MB-231/ ADR cells than that in their parental MCF-7 and MDA-MB-231 cells, respectively ( Figure 1B and C) . In addition, we detected that the MCF-7 parental and resistant cells showed a more significant difference in the expression of miR-30c, as well as YWHAZ. These results potentially indicated that loss of miR-30c might be associated with overexpression of YWHAZ in breast doxorubicin-resistant cells.
Overexpression of miR-30c sensitized MCF-7/ADR cells to doxorubicin
In the next series of studies, we established the relationship between miR-30c expression and doxorubicin resistance using MCF-7/ADR and its parental cell line MCF-7 because of the significant difference in miR-30c expression. As shown in Figure 2A , the level of drug resistance between the parent and resistant cells was 36.5 times (IC 50 was 0.331±0.121 mg/mL for MCF-7 and 12.078±0.368 mg/mL for MCF-7/ADR, respectively, P,0.05). To investigate whether miR-30c modulated chemosensitivity in breast cancer, we transfected 80 nM miR-30c mimic or negative control into MCF-7/ADR cells. Stem-loop real-time PCR revealed that the miR30c mimic significantly increased miR-30c expression, suggesting that miR-30c was efficiently transfected into cells ( Figure 2B ). In the CCK-8 assay, MCF-7/ADR cells transfected with miR-30c mimic exhibited greatly enhanced sensitivity to doxorubicin, compared with those transfected with the control miRNA mimic (IC 50 was 4.008±0.342 and 10.977±0.275 mg/mL, respectively; P,0.05; Figure 2C ), suggesting the role of miR30c in mediating sensitivity to doxorubicin in breast cancer cells. In order to strengthen this argument, we observed the intracellular accumulation of doxorubicin in MCF-7/ADR cells under a fluorescence microscope. As shown in Figure 2D , intracellular accumulation of doxorubicin was increased in cells treated with miR-30c mimic in comparison with control cells. Furthermore, we examined the effect of miR-30c overexpression on apoptotic cell death. A flow cytometry assay for miR30c verified that breast cancer cells transfected with miR-30c mimic had a significantly higher apoptosis rate than the negative control group induced by doxorubicin (P,0.01; Figure 2E ). These results demonstrated that miR-30c restoration sensitizes MCF-7/ADR cells to doxorubicin.
miR-30c suppressed expression of the YWHAZ gene
To explore the downstream mechanism through which miR-30c modulates doxorubicin resistance, we first used the algorithms for target gene prediction, including TargetScan and miRanda, and found that YWHZA was the potential target gene of miR-30c ( Figure 3A) . To further detect whether YWHAZ is the target gene of miR-30c, we cotransfected miR-30c mimic or the negative control together with the luciferase reporter plasmid with the 39-UTR of YWHAZ into MCF-7/ ADR cells. As shown in Figure 3B , reporter activity of the 39-UTR of YWHAZ was significantly suppressed by miR30c mimic, whereas mutant YWHAZ 39-UTR-luciferase activity remained unchanged in cells transfected with miR-30c mimic. These results indicated that YWHAZ was the target gene of miR-30c. We consequently conducted further analysis to explore whether miR-30c regulated YWHAZ expression in MCF-7/ADR cells. Results showed YWHAZ was a key signal molecule in doxorubicin resistance by reducing activation of the p38MAPK signal pathway in MCF-7/ADR cells Previous studies have shown that YWHAZ is involved in drug resistance in breast cancer cells (12) . However, its Student t-test) . B, qRT-PCR showed that the expression of miR-30c significantly increased in the cells transfected with miR30c mimic (*P,0.05, Student t-test). C, After transfection with miR-30c mimic or negative control (NC) for 48 h, MCF-7/ADR cells were subsequently treated with various doses of doxorubicin for 48 h. Cell viability was determined using the CCK-8 assay. The IC 50 of miR-30c mimic and NC groups was 4.008±0.342 and 10.977±0.275 mg/mL (*P,0.05, Student t-test). D, After incubation with 5 mM doxorubicin for 2 h, the cells were washed three times with PBS, and then observed under a fluorescence microscope with a 4006 lens. The intracellular accumulation of doxorubicin was more significant in the mimic group as indicated by arrows. E, Overexpression of miR-30c in MCF-7/ADR cells rescued doxorubicin-induced apoptosis after 48 h of 1 mM doxorubicin treatment.
role in doxorubicin resistance in MCF-7/ADR cells remains unclear. To determine the impact of YWHAZ alone on cell viability, we transfected siRNA against YWHAZ or a negative control into MCF-7/ADR cells, followed by treatment with various doses of doxorubicin. The results suggested that YWHAZ siRNA effectively reduced protein levels of YWHAZ ( Figure 4A and B) , and, as shown in Figure 4D , the MCF-7/ADR cells that were transfected with YWHAZ siRNA had a lower survival rate than the negative control group (IC 50 was 3.125±0.401 mg/mL for the siYWHAZ group and 10.178±0.344 mg/mL for the negative control group, respectively, P,0.05). Moreover, the survival pattern of MCF-7/ADR cells transfected with YWHAZ siRNA was similar to that of cells with miR-30c overexpression. For the above-mentioned results, we suggested that miR-30c modulated doxorubicin resistance in MCF-7/ADR cells by downregulating YWHAZ. Notably, it has been reported that the activated p38MAPK pathway plays a causal role in chemotherapy-induced apoptosis in resistant cells (13, 14) . It has also been reported that enhanced chemosensitivity by suppression of YWHAZ seems to be associated with activation of the p38MAPK pathway (15) . Therefore, we examined the impact of miR30c on the p38MAPK pathway and found that the level of p38MAPK phosphorylation was increased, along with the reduction of YWHAZ expression levels ( Figure 3D ). We also observed that the level of p38MAPK phosphorylation in siYWHAZ-transfected cells was increased compared to controls and scrambled siRNA-transfected cells ( Figure 4A and C). Therefore, we concluded that overexpression of miR-30c may activate the p38MAPK pathway by reducing protein levels of YWHAZ to enhance doxorubicin sensitivity in MCF-7/ADR cells; however, the mechanism remains to be further studied.
miR-30c regulated doxorubicin resistance in vivo
Nude mice with doxorubicin-resistant human breast cancer and sc passage of MCF-7/ADR were used to validate the role of miR-30c as a regulator of breast tumor progression in vivo. As shown in Figure 5A , the tumor size of the miR-30c mimic group was significantly smaller than that of the negative control group. Tumor growth was much slower for the group given doxorubicin and miR-30c mimic compared with the negative control group ( Figure 5B ). Taken together, at a dose of 1 mg/kg, doxorubicin did not inhibit tumor growth in the negative control group, but significantly inhibited the growth of tumor cells in the miR30c overexpression group. We, therefore, identified miR-30c 
Discussion
Breast cancer is a heterogeneous disease due to a complicated etiology involving both genetic and environmental factors. Although advances in both diagnosis and treatment, which incorporates surgery, radiation therapy, and chemotherapy, have led to the improvement of prognosis (16, 17) , chemotherapy resistance remains a major challenge in breast cancer therapy. Previous studies have shown that miRNA could serve as an ''oncogene'' or ''tumor suppressor gene'' and regulate different cellular processes by targeting hundreds of genes (18) (19) (20) (21) (22) . Functional studies indicate that miRNAs participate in regulating almost every cellular process, including drug resistance. However, the role of miRNA in drug resistance in tumor cells remains largely unexplored. In this report, the molecular mechanism involved in miR30c and its specific target YWHAZ in MCF-7/ADR provided new evidence for the development of drug resistance in cancer cells.
Recently, an increasing number of studies have focused on the anticancer properties of miR-30c, showing deregulation of miR-30c expression in a variety of human cancers (23) (24) (25) (26) . For example, Rodriguez-Gonzalez et al. (27) reported miRNA-30c as an independent predictor of the clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Mu and Su (28) showed that the single nucleotide polymorphism A/G in pre-miR-30c might be associated with a high risk of gastric cancer. miRNA has also been shown to potentially act as a tumor suppressor in these tumors. However, the biological relationship between miR-30c and its specific target YWHAZ in doxorubicin resistance in MCF-7/ADR cells remains unknown.
Targeting at the apoptotic pathway could be an attractive and therapeutically beneficial option because chemotherapeutically induced cell death is generally programmed by apoptosis (29) . YWHAZ codes for a known anti-apoptotic protein, 14-3-3f, which is a member of the highly conserved family of seven 14-3-3 proteins, all encoded by different genes (30) . YWHAZ serves as a pivotal factor that binds and stabilizes key proteins involved in signal transduction, cell proliferation, and apoptosis, including EGFR, HER2, PKC, b-catenin, and RAF-1 (31) (32) (33) (34) . Additionally, overexpression of YWHAZ contributed to de novo chemoresistance to anthracyclines and is permissive for metastatic recurrence (12) . Moreover, p38MAPK signaling is well known as an independent parallel MAPK pathway that is believed to play an important role in apoptosis, and the activation of p38MAPK phosphorylation reverses resistance to apoptosis in different types of tumors, including breast carcinoma (35, 36) . Furthermore, the anti-apoptotic gene YWHAZ specifically regulates the p38MAPK signaling pathway, playing a key role in tumor formation and drug resistance (15, 37) . Together, we can hypothesize that overexpression of miR-30c may result in reduced expression of YWHAZ as well as its downstream p38MAPK pathway, and, therefore, may reverse doxorubicin resistance in MCF-7/ADR cells.
To confirm this hypothesis, we first examined the expression of miR-30c and found that the level of expression was significantly decreased in doxorubicinresistant cell lines MCF-7/ADR and MDA-MB-231/ADR, compared with their corresponding parental cell lines MCF-7 and MDA-MB-231, respectively, which indicated that reduced miR-30c levels may be associated with doxorubicin resistance in breast cancer. To further investigate the function of miR-30c, we predicted binding sites for miR-30c in the YWHAZ 39-UTR by bioinformatic analysis. Western blot assay indicated that increased expression of miR-30c might have an impact on YWHAZ expression. Furthermore, we demonstrated that YWHAZ was a target gene of miR-30c by luciferase reporter assay. Then, we transfected the chemically synthesized miR-30c mimic oligonucleotides or YWHAZ siRNA into MCF-7/ADR cells. Results showed that restoration of miR-30c or inhibition of YWHAZ in MCF-7/ADR cells sensitized MCF-7/ADR cells to doxorubicin. Importantly, experiments in vivo showed that doxorubicin significantly inhibited the growth of tumor cells in the miR-30c overexpression group, but not in the negative control group, which strongly confirmed our argument. Consistent with these findings, we also found that overexpression of miR-30c led to downregulation of YWHAZ and a more active signaling through the p38MAPK pathway, which contributed to reversing doxorubicin resistance in MCF-7/ ADR cells.
In conclusion, we provided direct evidence that miR30c restoration sensitizes MCF-7/ADR to doxorubicin treatment in vivo and in vitro. Furthermore, we documented miR-30c as a potential tumor suppressor of the progression to doxorubicin resistance in breast cancer through its ability to target YWHAZ and the p38MAPK signaling pathway, providing new mechanistic insights into the function of miRNA as a potential therapy for a variety of cancers. Finally, the therapeutic modulation of miR-30c and other miRNAs might be worth exploring in an attempt to improve drug efficacy by overcoming mechanisms of resistance. 
